naltrexone has been researched along with Nicotine Addiction in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.56) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Bardo, MT; Chandler, CM; Maggio, SE; Nixon, K; Peng, H | 1 |
| Bernstein, SL; D'Onofrio, G | 1 |
| Bardo, MT; Bell, RL; Crooks, PA; Dwoskin, LP; Maggio, SE; Nixon, K; Prendergast, MA; Saunders, MA; Zheng, G | 1 |
| Cioe, PA; Kahler, CW; Lechner, WV; Sidhu, NK | 1 |
| Hauser, SR; Knight, CP; McBride, WJ; Pratt, LA; Rodd, ZA; Waeiss, RA | 1 |
| Gorelick, DA; Mannelli, P; Peindl, KS; Wu, LT | 1 |
| Douaihy, AB; Kelly, TM; Sullivan, C | 1 |
| Coen, K; Funk, D; Grella, SL; Lê, AD; Li, Z | 1 |
| Bress, A; Hooker, SE; King, A; Kittles, R; Wing, C | 1 |
| Willyard, C | 1 |
| Dowling, NA; Lorains, FK; Merkouris, SS | 1 |
| Klein, JW | 1 |
| Capurso, NA | 1 |
| al'Absi, M; Hatsukami, D; Westra, R; Wittmers, LE | 1 |
| McKee, SA | 1 |
| Berrendero, F; Maldonado, R; Martín-García, E; Robledo, P; Trigo, JM | 1 |
| Ismayilova, N; Shoaib, M | 1 |
| Natividad, LA; O'Dell, LE; Orfila, JE; Tejeda, HA; Torres, OV | 1 |
| Cai, X; Cao, D; deWit, H; King, AC; Kranzler, HR; Matthews, AK; O'Malley, SS; Stachoviak, RJ | 1 |
| Frost, JJ; Kuwabara, H; McCaul, ME; Wand, GS; Weerts, EM; Wong, DF; Xu, X | 1 |
| Modesto-Lowe, V; Van Kirk, J | 1 |
| Krishnan-Sarin, S; Meandzija, B; O'Malley, S | 1 |
| Hampton, T | 1 |
| Hagan, JJ; Heidbreder, CA | 1 |
| Jepson, C; Lerman, C; Lynch, KG; Patterson, F; Perkins, K; Rukstalis, M; Strasser, A | 1 |
| Byars, JA; Frost-Pineda, K; Gold, MS; Jacobs, WS | 1 |
| Chae, SL; Joe, KH; Kee, BS; Lee, YS; Na, C; Sohn, IK | 1 |
| O'Brien, CP | 1 |
| Breteler, MH; Kerkhof, AJ; Postmus, PE; Roozen, HG; Van Beers, SE; Weevers, HJ; Willemsen, MC | 1 |
| Beilby, JJ; Doran, CM; Duszynski, KM; Mattick, RP | 1 |
| Diehl, A; Mann, K | 1 |
| Jatlow, P; Martin, DJ; McKee, SA; O'Malley, SS; Toll, BA | 1 |
| Blendy, J; Jepson, C; Lerman, C; Patterson, F; Perkins, K; Ray, R; Rukstalis, M; Strasser, AA; Wileyto, P | 1 |
| Allen, JP; Litten, RZ | 1 |
| Covey, LS; Glassman, AH; Stetner, F | 1 |
| King, AC; Meyer, PJ | 1 |
10 review(s) available for naltrexone and Nicotine Addiction
| Article | Year |
|---|---|
Medications for substance use disorders.
Topics: Alcohol Deterrents; Alcoholism; Analgesics, Opioid; Behavior Therapy; Behavior, Addictive; Buprenorphine; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Disorder | 2013 |
Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research.
Topics: Acetylcysteine; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Bipolar Disorder; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Free Radical Scavengers; Gambling; Humans; Lithium Compounds; Mental Disorders; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Tobacco Use Disorder | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Developing human laboratory models of smoking lapse behavior for medication screening.
Topics: Alcohol Drinking; Arousal; Bupropion; Cues; Drug Evaluation, Preclinical; Humans; Models, Psychological; Motivation; Naltrexone; Nicotine; Psychotropic Drugs; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Social Environment; Social Facilitation; Tobacco Use Disorder | 2009 |
Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.
Topics: Animals; Behavior, Addictive; Humans; Motivation; Naltrexone; Neurotransmitter Agents; Nicotine; Opioid Peptides; Receptors, Nicotinic; Reinforcement, Psychology; Reward; Smoking Cessation; Tobacco Use Disorder | 2010 |
Clinical uses of naltrexone: a review of the evidence.
Topics: Alcoholism; Animals; Behavior, Addictive; Cocaine-Related Disorders; Feeding and Eating Disorders; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Opioid-Related Disorders; Schizophrenia; Self-Injurious Behavior; Substance-Related Disorders; Tobacco Use Disorder | 2002 |
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
Topics: Alcoholism; Clinical Trials as Topic; Cocaine-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Opioid-Related Disorders; Structure-Activity Relationship; Substance-Related Disorders; Tobacco Use Disorder | 2005 |
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
Topics: Alcoholism; Behavior, Addictive; Bupropion; Cocaine-Related Disorders; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Psychotropic Drugs; Secondary Prevention; Substance-Related Disorders; Tobacco Use Disorder | 2005 |
[Pharmacological relapse prevention in alcohol and tobacco dependence].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Disulfiram; Humans; Naltrexone; Nicotine; Psychotherapy; Secondary Prevention; Smoking Cessation; Substance Withdrawal Syndrome; Taurine; Tobacco Use Disorder | 2007 |
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Bupropion; Forecasting; Humans; Methadyl Acetate; Naltrexone; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 1999 |
11 trial(s) available for naltrexone and Nicotine Addiction
| Article | Year |
|---|---|
Effects of time-varying changes in tobacco and alcohol use on depressive symptoms following pharmaco-behavioral treatment for smoking and heavy drinking.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Smoking Cessation; Time Factors; Tobacco Smoking; Tobacco Use Disorder | 2019 |
Smoking and opioid detoxification: behavioral changes and response to treatment.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Naltrexone; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2013 |
Blunted opiate modulation of hypothalamic-pituitary-adrenocortical activity in men and women who smoke.
Topics: Adrenocorticotropic Hormone; Arousal; Double-Blind Method; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Naltrexone; Narcotic Antagonists; Nicotine; Opioid Peptides; Pain Measurement; Pain Threshold; Pituitary-Adrenal System; Saliva; Sex Factors; Thermosensing; Tobacco Use Disorder; Young Adult | 2008 |
Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.
Topics: Administration, Oral; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sex Factors; Smoking Cessation; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Weight Gain | 2012 |
Naltrexone and nicotine patch smoking cessation: a preliminary study.
Topics: Administration, Cutaneous; Adult; Female; Ganglionic Stimulants; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Placebos; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome | 2003 |
Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm.
Topics: Adolescent; Adult; Aged; Bupropion; Choice Behavior; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Reinforcement, Psychology; Smoking Cessation; Tobacco Use Disorder | 2005 |
Naltrexone augments the effects of nicotine replacement therapy in female smokers.
Topics: Administration, Cutaneous; Administration, Topical; Adult; Combined Modality Therapy; Double-Blind Method; Female; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Psychotherapy; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder | 2005 |
Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment.
Topics: Adrenocorticotropic Hormone; Adult; Carbon Monoxide; Double-Blind Method; Endorphins; Hormones; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists; Prolactin; Smoking; Surveys and Questionnaires; Tobacco Use Disorder | 2005 |
Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Netherlands; Pneumothorax; Smoking Cessation; Tobacco Use Disorder | 2006 |
Naltrexone effects on short-term and long-term smoking cessation.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Smoking Cessation; Time Factors; Tobacco Use Disorder | 1999 |
Naltrexone alteration of acute smoking response in nicotine-dependent subjects.
Topics: Adult; Affect; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2000 |
15 other study(ies) available for naltrexone and Nicotine Addiction
| Article | Year |
|---|---|
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Male; Naltrexone; Nicotine; Rats; Rats, Sprague-Dawley; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2020 |
Screening, treatment initiation, and referral for substance use disorders.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Mass Screening; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Tobacco Use Disorder | 2017 |
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Disease Models, Animal; Ethanol; Female; Naltrexone; Nicotine; Nicotinic Antagonists; Picolines; Pyridinium Compounds; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2018 |
Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.
Topics: Alcohol Deterrents; Alcohol Drinking; Animals; Ethanol; Female; Injections, Subcutaneous; Naltrexone; Nicotine; Random Allocation; Rats; Self Administration; Smoking Cessation Agents; Tobacco Use Disorder; Varenicline | 2019 |
Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic alpha-2 Receptor Antagonists; Analgesics, Non-Narcotic; Animals; Conditioning, Operant; Drug Administration Schedule; Drug Interactions; Extinction, Psychological; Male; Naltrexone; Nicotine; Nicotinic Agonists; Rats; Rats, Long-Evans; Receptors, Opioid, kappa; Self Administration; Stress, Psychological; Tobacco Use Disorder; Yohimbine | 2014 |
Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial.
Topics: Adult; Black or African American; Female; Genotype; Humans; Male; Middle Aged; Naltrexone; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Smoking; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; White People | 2015 |
Pharmacotherapy: Quest for the quitting pill.
Topics: Animals; Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Clinical Trials as Topic; Cocaine-Related Disorders; Counseling; Dopamine; Drug Discovery; Drug Industry; Humans; Ibogaine; Lobeline; Molecular Targeted Therapy; Naloxone; Naltrexone; Oligopeptides; Opioid-Related Disorders; Pleasure; Rats; Receptors, Nicotinic; Reward; Substance-Related Disorders; Tobacco Use Disorder; Vaccines; Vesicular Monoamine Transport Proteins | 2015 |
Naltrexone for the treatment of comorbid tobacco and pornography addiction.
Topics: Aged; Behavior, Addictive; Erotica; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome | 2017 |
Alteration of intravenous nicotine self-administration by opioid receptor agonist and antagonists in rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Dose-Response Relationship, Drug; Feeding Behavior; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nicotine; Rats; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration; Tobacco Use Disorder | 2010 |
Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Aging; Animals; Behavior, Animal; Dopamine; Dose-Response Relationship, Drug; Male; Naltrexone; Nicotine; Nucleus Accumbens; Rats; Rats, Wistar; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2012 |
Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.
Topics: Adult; Alcoholism; Brain; Brain Mapping; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Receptors, Opioid, mu; Severity of Illness Index; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Cessation Devices; Tobacco Use Disorder | 2014 |
Genes harbor clues to addiction, recovery.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Receptors, Dopamine D2; Receptors, Opioid, mu; Tobacco Use Disorder | 2004 |
Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Australia; Bupropion; Dopamine Uptake Inhibitors; Female; Health Care Surveys; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Substance-Related Disorders; Taurine; Tobacco Use Disorder | 2006 |
Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.
Topics: Adult; Attitude to Health; Factor Analysis, Statistical; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nicotine; Patient Compliance; Psychometrics; Reproducibility of Results; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Tobacco Use Disorder | 2007 |
CREB1 haplotypes and the relative reinforcing value of nicotine.
Topics: Association Learning; Case-Control Studies; Choice Behavior; Cyclic AMP Response Element-Binding Protein; Double-Blind Method; Haplotypes; Humans; Linkage Disequilibrium; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; Regression Analysis; Reward; Smoking; Tobacco Use Disorder | 2007 |